Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services ...